Benign hereditary chorea: clinical and neuroimaging features in an Italian family. by Salvatore E et al.
Huntington’s disease gene test Nat Clin Pract Neurol 2007;
3:517–525.
4. Dobson-Stone C, Velayos-Baeza A, Filippone LA, et al. Chorein
detection for the diagnosis of chorea-acanthocytosis Ann Neurol
2004;56:299–302.
5. Dobson-Stone C, Velayos-Baeza A, Jansen A, et al. Identification
of a VPS13A founder mutation in French Canadian families with
chorea-acanthocytosis Neurogenetics 2005;6:151–158.
6. Al-Asmi A, Jansen AC, Badhwar A, et al. Familial temporal
lobe epilepsy as a presenting feature of choreoacanthocytosis
Epilepsia 2005;46:1256–1263.
7. Hardie RJ, Pullon HW, Harding AE, et al. Neuroacanthocytosis.
A clinical, haematological and pathological study of 19 cases
Brain 1991;114:13–49.
8. Dobson-Stone C, Danek A, Rampoldi L, et al. Mutational spec-
trum of the CHAC gene in patients with chorea-acanthocytosis
Eur J Hum Genet 2002;10:773–781.
9. Walker RH, Liu Q, Ichiba M, et al. Self-mutilation in chorea-
acanthocytosis: manifestation of movement disorder or psychopa-
thology? Mov Disord 2006;21:2268–2269.
10. Chew NK, Mir P, Edwards MJ, et al. The natural history of
Unverricht-Lundborg disease: a report of eight genetically proven
cases Mov Disord 2008;23:107–113.
11. Shoumitro DEB. Self-injurious behaviour as part of genetic syn-
dromes BR J PSYCH 1998;172:385–388.
12. Espelin DE, Done AK. Amphetamine poisoning: effect-
iveness of chlorpromazine N Engl J Med 1968;278:1361–
1365.
13. Mangiarini L, Sathasivam K, Seller M, et al. Exon 1 of the HD
gene with an expanded CAG repeat is sufficient to cause a pro-
gressive neurological phenotype in transgenic mice Cell 1996;
87:493–506.
14. Storch A, Kornhass M, Schwarz J. Testing for acanthocytosis a
prospective reader-blinded study in movement disorder patients
J Neurol 2005;252:84–90.
15. Walker RH, Jung HH, Dobson-Stone C, et al. Neurologic phe-
notypes associated with acanthocytosis Neurology 2007;68:92–
98.
Benign Hereditary Chorea:
Clinical and Neuroimaging
Features in an Italian Family
Elena Salvatore, MD, PhD,1 Luigi Di Maio, MD, PhD,1
Alessandro Filla, MD,1 Alfonso M. Ferrara, MD,2
Carlo Rinaldi, MD,1 Francesco Sacca`, MD,1
Silvio Peluso, MD,1 Paolo E. Macchia, MD, PhD,2
Sabina Pappata`, MD,3 and Giuseppe De Michele, MD1*
1Department of Neurological Sciences, Federico II
University, Naples, Italy; 2Department of Endocrinology and
Molecular and Clinical Oncology, Federico II University,
Naples, Italy; 3Biostructure and Bioimaging Institute, CNR,
Naples, Italy
Video
Abstract: Benign hereditary chorea is an autosomal domi-
nant disorder characterized by early onset nonprogressive
chorea, caused by mutations of the thyroid transcription
factor-1 (TITF-1) gene. Clinical heterogeneity has been
reported and thyroid and respiratory abnormalities may
be present. We describe 3 patients of an Italian family
carrying the S145X mutation in the TITF-1 gene with
mild motor delay, childhood onset dyskinesias, and subtle
cognitive impairment. A child in the third generation pre-
sented with congenital hypothyroidism and neonatal respi-
ratory distress. Imaging studies in 2 patients showed mild
ventricular enlargement and empty sella at magnetic reso-
nance imaging and hypometabolism of basal ganglia and
cortex at 18-Fluoro-2-deoxy-glucose positron emission
tomography. ! 2010 Movement Disorder Society
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Benign hereditary chorea (BHC) is an autosomal
dominant disorder characterized by childhood onset
chorea with little or no progression into adult life.
Mental deterioration does not occur, but slightly lower
I.Q. scores have been reported. Mutations in the thy-
roid transcription factor-1 (TITF-1) gene on chromo-
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some 14q have been identified as causative in several
families, most of them recently reviewed.1,2 A second
locus (8q21) for BHC has been recently mapped in
two Japanese families with adult onset chorea.3
The TITF-1 gene is a homeodomain-containing tran-
scription factor essential for the organogenesis of lung,
thyroid, and basal ganglia.4 Thus, it is not surprising
that the clinical spectrum in families carrying TITF-1
mutations includes thyroid and lung disorders, such as
congenital hypothyroidism and respiratory distress. The
putative mechanism of disease results from gene hap-
loinsufficiency and reduced protein product.
We previously described molecular and functional
data of the novel TITF-1 S145X mutation in an Italian
pedigree.5 Here, we report in detail the clinical features
and the neuroimaging data of the family.
CASE REPORTS
This three-generation family shows three affected
individuals, one for each generation, all carrying a pre-
viously unreported mutation of the TITF-1 gene. The
genetic defect and the molecular mechanisms have
been described in the previous article.5 The index
patient was Patient 1, who had been referred for exclu-
sion of Huntington’s disease (HD). The information
that her father (Pt. 2) had abnormal movements and
that her son (Pt. 3) had congenital hypothyroidism led
to the clinical suspicion of BHC and to the molecular
analysis of the TITF-1 gene.
Patient 1, 26 years old, began walking at the age of
18 months, but she was clumsy and fell repeatedly.
Her gait much improved around puberty. Mild general-
ized choreic movements appeared at the age of 7 years
and remained stable thereafter. No mental or behav-
ioral abnormalities were present, she did not encounter
difficulties at school, and she was graduated at a Hotel
school. During puerperium, when she was 19 years
old, her chorea worsened and she presented with a
postpartum psychosis, characterized by depression and
aggressiveness toward the newborn and successfully
treated with risperidone and lamotrigine.
At the age of 23 years she was admitted to our hos-
pital. Neurological examination showed generalized
choreic movements (video) and was otherwise normal.
Neuropsychological evaluation demonstrated long term
verbal memory deficit and low-normal score at Raven
Matrices test.
Molecular analysis of HD gene and laboratory test-
ing were normal, a part from elevation of thyroid-stim-
ulating hormone.5 Thyroid hormone replacement was
started. Brain magnetic resonance imaging (MRI)
revealed ventricular dilatation, more marked in the
posterior part of lateral ventricles (Fig. 1a–c) and par-
tial empty sella (Fig. 1d). Brain 18-Fluoro-2-Deoxy-
Glucose Positron Emission Tomography (FDG-PET)
showed slight relative hypometabolism of the caudate
nuclei and of the medial frontal and temporo-parietal
cortices (Fig. 2). The patient was treated with tetrabe-
nazine up to 75 mg daily, with mild improvement. At
the age of 26 years she withdrew the therapy abruptly
and presented marked worsening of chorea, irritability,
emotional lability, poor sleep, inappropriate dress, and
behavior. She was admitted to our hospital again,
treated with quetiapine, 75 mg/daily, and discharged
improved after a week.
Patient 2, the proband’s father, 56 years old, had
meningitis at the age of 6 months. Subsequent motor
development was delayed with walking starting at the
age of 5 years and normal language skills. His school
performances were poor. Since childhood, slight, spo-
radic, hyperkinesias were present, which mainly
involved the abdomen and had been stable over time.
He did not report improvement by alcohol. He worked
as a school-caretaker and had a normal social life. At
examination jerky abdominal movements were evident;
mild and rare choreic movements were present in other
body regions (video). Neuropsychological evaluation
showed short term verbal and spatial memory deficit,
slight attentional deficit, and constructive apraxia.
Thyroid hormone screening showed primary hypo-
thyroidism with increased TSH and mildly reduced
FT3. Brain MRI evidenced slight, asymmetrical ven-
tricular dilatation, more marked in the right side and in
the posterior part of lateral ventricles (Fig. 1e–g), and
complete empty sella (Fig. 1h). FDG-PET demon-
strated relative hypometabolism of basal ganglia, more
prominent in the caudate nuclei, and a slight relative
hypometabolism of the left temporo-parieto-occipital
cortex (Fig. 2). Tetrabenazine, up to 50 mg daily, was
prescribed, but the drug was withdrawn for insomnia
and nervousness.
Patient 3, the 5 years old proband’s son, born at term
by cesarean delivery because of transverse position,
received continuous positive airway pressure therapy
for neonatal respiratory distress. The infant presented
with multiple congenital anomalies: severe bilateral
vesicoureteral reflux with pyelectasis and megabladder,
patent foramen ovale, and congenital hypothyroidism
for which thyroid replacement treatment was started.
Psychomotor development was delayed: sitting at
10 months, walking at 26 months, first words at 26
months, at present only few words in vocabulary and
lack of sphincter control. His I.Q. was 76 at the age of
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4 years. He is a pleasant boy, has no behavioral prob-
lem and developed normal social relationships. At the
age of 4 years he developed slight, generalized choreic
movements (video).
Molecular analysis: Direct sequencing of the TITF-1
gene showed, in all the 3 patients, the new heterozy-
gous mutation C609A in exon 2, resulting in a substi-
tution of serine at codon 145 for a stop codon
(S145X). The mutation predicted a truncated protein of
about 14.5 kDa that lacks the entire homeodomain and
the carboxy-terminus portion.5
DISCUSSION
BHC shows heterogeneity of the clinical presentation
within and among the families. In the present family
the neurologic presentation, characterized by mild
motor delay, early-onset dyskinesias, and slightly lower
intelligence, was quite similar in the 3 patients,
although the abnormal movements are somewhat differ-
ent among individuals. Although chorea is the move-
ment disorder characteristic of BHC, dystonia, myo-
clonic jerks, and ataxia have been also described.6 The
distinction among chorea, myoclonus, and jerky dysto-
nia may be difficult. The diagnosis of chorea, which is
characterized by a random flow of rapid, unpredictable
abnormal movements,7 better applies to Patients. 1 and
3, whereas the sudden, more predictable and repetitive
abdominal jerks in Patient 2 seem to be more consistent
with myoclonus. As described in other patients with
BHC,6 dyskinesias, contrary to myoclonus-dystonia,
were not worsened by action nor improved by alcohol.
Concerning extra-neurologic features subclinical
hypothyroidism was present in Patients 1 and 2, whereas
FIG. 1. Axial T2-weighted (Pt. 1 a–c; Pt. 2 e–g) and sagittal T1-weighted (Pt. 1 d; Pt. 2 h) MR images. Dilatation of supratentorial ventricular
system is evident in both patients. Enlargement of the third ventricle is also evident in Patient 2. In both patients there is evidence of empty sella,
partial in Patient 1, complete and prominent in Patient 2.
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Patient 3 had congenital hypothyroidism and neonatal
respiratory distress. Anticipation and more severe phe-
notype in subsequent generations have been suggested,8
but not demonstrated in BHC. Environmental factors
and genetic background might also influence the clinical
expression. A review of the reported cases1,2,6,9–16
reveals 11 cases of congenital hypothyroidism due to
TITF-1 mutations in patients with de novo mutations or
with no information about parental phenotype or geno-
type, 11 (including the present one) with maternal inher-
itance of the allele carrying the mutation, and one with
paternal inheritance.16 However, there are also reports of
maternal inheritance without congenital hypothyroidism.
The predominance of maternal inheritance of congenital
hypothyroidism in BHC may be due to chance or may
be related to imprinting or maternal environment.
It remains unclear if some peculiar features of our
patients, as postpartum psychosis in Patient 1 and urinary
tract malformations in Patient 3, are related to the muta-
tion. Psychosis occurred in two previously reported
patients16,17 and hypospadia has been described before
recognition of the molecular defect.18,19 We are not
aware of a role of TITF-1 in urinary tracts organogenesis,
although the gene is expressed in small cell carcinoma of
the urinary bladder.20 We suggest special attention to uri-
nary tract malformations in patients with BHC.
Imaging data also appear to be heterogeneous in
BHC. CT/MRI findings are usually normal, but ventric-
ular dilatation and other abnormalities have been also
reported.10,21,22 A cystic mass in the posterior part of
the sella turcica has been described in two cases.22 In
the 2 patients investigated by us, MRI showed ventric-
ular dilatation, more evident at trigone and occipital
horn level, whereas in HD ventricular enlargement
mostly affects the frontal horns.23 Empty sella was
present in both patients, more marked in Patient 2,
which has the longest disease duration. Haploinsuffi-
ciency of the TITF-1 gene could lead to congenital
deficiency of the sellar diaphragm, which is a frequent
cause of an enlarged sella. FDG-PET scan was
reported to be normal in 4 patients with BHC,9
although a study performed when the molecular diag-
FIG. 2. Axial images of brain 18F-deoxy-glucose uptake obtained with PET in a 39 years control, in Patient 1 and in Patient 2. The images were
spatially normalized into the Montreal Neurological Institute (MNI) space and normalized to globals. The scale shows values of highest uptake in
red and lowest uptake in blue. In Patient 1 a mild reduction of tracer uptake is present in the caudate nuclei and in the medial frontal and tem-
poro-parietal cortex, bilaterally. The basal ganglia hypometabolism is more marked in Patient 2, involving more the caudate than the putamen
regions. In Patient 2 there is also a mild temporo-parietal metabolism reduction on the left side. L left, R right.
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nosis was not available showed caudate hypometabo-
lism.24 More recently reduction of technetium 99 m
ethyl cysteinate dimer uptake has been demonstrated in
the basal ganglia of two children studied by SPECT.25
Using FDG-PET we showed cortex and basal ganglia
hypometabolism in both Patient 1 and Patient 2. These
findings are consistent with the significant reduction of
striatal and neocortical interneurons demonstrated by
immunohistochemical staining in BHC26 and with the
patients’ choreic syndrome and mild cognitive impair-
ment. The pattern of metabolic changes is similar, but
less severe than that found in HD,23 consistently with
the milder, non progressive BHC phenotype.
Legends to the Videos
Segment 1. Patient 1 examination shows general-
ized, moderate to marked, choreic movements involv-
ing the face, the neck, the trunk, the limbs, both proxi-
mally and distally. Finger-to-nose and walking do not
worsen the abnormal movements. Mild unsteadiness is
also evident.
Segment 2. Slightly staggering gait and mild limb
choreic movements, not worsened by action, in Patient
2. Brisk abdominal wall contractions are evident.
Segment 3. In Patient 3 mild choreic movements
involved the trunk and the four limbs, both proximally
and distally, not worsened by action. Brisk myoclonic-
like movements are also evident. Tottering was prob-
ably too marked for his age.
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Abstract: Unilateral pallidotomy has been effectively used
to treat parkinsonism and reduce levodopa induced dyski-
nesia (LID). We sought to determine the long-term effects
of pallidotomy on LID in 10 patients who had initial
benefit from pallidotomy but went on to require DBS sur-
gery for symptom progression. The Dyskinesia Rating
Scale (DRS) was used to rate and quantify LID in a
blinded fashion. Though sample size was small, there was
a trend towards a reduction in LID lasting up to 12 years
suggesting that posteroventral pallidotomy may provide
sustained benefit in reducing LID. ! 2010 Movement
Disorder Society
Key words: Parkinson’s disease; pallidotomy; dyskinesia
In the era before DBS, as well as currently, in many
countries around the world, unilateral postero-ventral
pallidotomy as a treatment for Parkinson’s disease
(PD) has been the surgical alternative of choice. Pallid-
otomy ameliorates parkinsonism and is particularly
effective in reducing levodopa-induced dyskinesia
(LID) most prominently in the contralateral hemibody.1
Despite initial control of disabling symptoms, parkin-
sonism generally worsens several years following pal-
lidotomy and many patients have subsequently under-
gone STN DBS when their symptoms again became re-
sistant to medical regimens.2–4
No long-term follow-up studies have blindly eval-
uated the persistent effects of unilateral pallidotomy on
LID. It has been our personal experience that the anti-
dyskinetic effects may be evident many years after the
original surgery and Hariz reported that these effects
could last up to 13.5 years.5
We sought to determine the long-term effect of pal-
lidotomy on dyskinesia in a selected sample of patients
who had previously undergone pallidotomy and were
undergoing preoperative evaluation for STN DBS due
to symptom progression. Given the extensive preopera-
tive assessment for DBS, ON/OFF evaluations were
available for review in these patients. We evaluated ef-
ficacy of pallidotomy on dyskinesia by comparing con-
tralateral and ipsilateral dyskinesia at the STN-DBS
preoperative evaluation. We postulated that there
would be a difference between sides due to lasting
effects of pallidal lesioning with less severe dyskinesia
contralateral to the previous surgery.
PATIENTS AND METHODS
Patient Population
Ten patients (8 male) with PD and prior pallidotomy
on average 7.3 years (range 2–12 years) earlier were
evaluated for consideration of STN DBS. All patients
were felt to have obtained an initial good response to
pallidotomy with respect to parkinsonism and particu-
larly LID. Not all patients had received pallidotomy at
our center; pre and postoperative LID scores were
available in 6 of the 10. Before DBS patients were
evaluated under the protocol of the Core Assessment
Program for Intracerebral Transplantation6 (CAPSIT)
before STN DBS surgery. Dyskinesia was assessed
using the Dyskinesia Rating Scale (DRS) (maximum
score for unilateral limbs 5 8). The dosage of anti-par-
kinsonian medication required by the patient was
recorded; levodopa equivalent doses (LED) were calcu-
lated in a manner described elsewhere.7 Evaluations
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